Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
4.02
-0.13 (-3.13%)
At close: Sep 25, 2025, 3:59 PM
4.04
0.50%
After-hours: Sep 25, 2025, 05:15 PM EDT
-3.13% (1D)
| Bid | 4 |
| Market Cap | 6.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10M |
| EPS (ttm) | -10.57 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | -0.94 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 4.14 |
| Volume | 47,917 |
| Avg. Volume (20D) | 73,584 |
| Open | 4.07 |
| Previous Close | 4.15 |
| Day's Range | 3.97 - 4.12 |
| 52-Week Range | 3.80 - 44.00 |
| Beta | -1.29 |
| Ex-Dividend Date | n/a |
About ACXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-12.25%
Acurx Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
3 months ago
+167.26%
Acurx Pharmaceuticals shares are trading higher after the company announced publication of its Phase 2 ibezapolstat study results in The Lancet.
1 month ago · seekingalpha.com
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call TranscriptAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants David P. Luci - Co-Founder, President, CEO, Corporate Secretary & Director R...